Myelin Regeneration in Mice with MS Achieved in Study

Stuart SchlossmanMS Research Study and Reports, Multiple Sclerosis, Stem Cell Related


                                                                  

  









Click here to receive MS news via e-mail




Therapies aimed at regenerating the myelin sheath can work to restore proper brain activity and may be a viable way of treating multiple sclerosis (MS), according to researchers at the University of California San Francisco.
In the study, “Accelerated Remyelination During Inflammatory Demyelination Prevents Axonal Loss And Improves Functional Recovery,” published in the journal eLife, researchers used mice with MS to understand exactly how remyelination could be triggered.
The myelin sheath — a coating made of myelin proteins that protects neurons and enhances the transmission of electrical impulses between them — is progressively lost in patients with MS, due to aberrant immune system attacks that destroy myelin. Myelin degeneration destabilizes neuronal function and ultimately leads to nerve cell death, contributing to disease progression and disability in MS patients. Many therapies have been developed in an attempt to promote remyelination and rescue neuronal function, but results did not support their viability.
“The key thing we learned from this study is that if we can design therapies that promote remyelination — especially when myelin has been damaged by inflammation as it is in MS — we can prevent neuronal loss and restore function,” the senior author of the study, Jonah Chan, PhD, said in a news release. “This is something I and other investigators have wanted to promise to MS patients, but we simply didn’t have the data.”
Researchers injected mice with a protein found in the myelin sheath that triggers a form of MS, called experimental autoimmune encephalomyelitis (EAE), which has an inflammatory response with physiological and behavioral consequences similar to those seen in human patients. At the same time, the mice also received an injection of clemastine, a drug the team had previously shown to be capable of promoting remyelination. This drug activates a group of proteins, called the muscarinic receptors, that are present in the cells that produce myelin, the oligodendrocytes.

Continue Reading







MS Views and News
Providing educational information, resources and services for those affected by MS

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews